The September 2022 meeting of the Research Board of the consortium tender 2018-1.3.1-VKE-2018-00030 - 2022 of MEDITOP Pharmaceuticals Ltd. and Semmelweis University summarized the already achieved results.
According to the information from the CRO company, 197 patients have been enrolled so far in the human Phase III clinical trial (for the add-on treatment of low back pain) under the tender sponsored by MEDITOP Pharmaceuticals Ltd, which means that the number of patients in the study protocol can be met by mid-2023.
Semmelweis Medical University Institute of Pharmacology
The results obtained from the studies conducted in the framework of this call have been published in the International Journal of Molecular Sciences, Lakatos et al. 2022;23(17):9564. doi: 10.3390/ijms23179564.
Semmelweis Medical University, Department of Neurology
The enrolment of patients suffering from acute low back pain in the clinical trial started in 2019 at the Neurological Clinic of Semmelweis University in collaboration with the Institute of Pharmacology is ongoing, and the planned trial is expected to be successfully completed in 2023.